1.1Ring oxygen at A
The divalent oxygen closes the five-membered fused ring and bonds directly to the ring nitrogen. The carbonyl elsewhere in the ring retains its position, giving a cyclic carbamate.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The divalent oxygen closes the five-membered fused ring and bonds directly to the ring nitrogen. The carbonyl elsewhere in the ring retains its position, giving a cyclic carbamate.
Ra1 attaches through sulfur as –S–CH3. Sulfur joins the scaffold to a single terminal methyl group and gives the substituent a longer bond to the scaffold than oxygen provides in a methoxy group.
The aromatic carbon bonds directly to the carbonyl carbon of –C(O)NH2. The carbonyl oxygen accepts hydrogen bonds and the amide NH groups donate hydrogen bonds.
The –CH2–CH2– segment joins the isoindoline ring to L through two tetrahedral carbons. Rotation about the central carbon–carbon bond gives the segment multiple conformations.
The cyclohexane connects the flanking groups at carbons 1 and 4 on opposite faces of the ring. Its diequatorial chair places both attachment bonds in equatorial positions.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A training kit uses an oxoisoindolinyl-substituted tetrahydropyrimidinedione and its corresponding deuterated analogue as reference compounds. The kit contains separate coded vials of each compound and a mixed reference vial. Liquid chromatography separates the components from sample impurities, and mass spectrometry distinguishes the two reference compounds by their molecular ion masses.
A dimethylphosphine oxide group replaces the terminal amide of a representative derivative. The linker bonds directly to phosphorus through a carbon–phosphorus bond, forming a terminal –P(=O)(CH₃)₂ group. The phosphoryl oxygen provides a hydrogen-bond acceptor at the distal end of the linker.
An N-methylsulfoximine replaces the sulfone connector between the isoindoline ring and the carbon end of the linker. Sulfur bonds to both fragments and carries an oxo group and an N-methyl imino group. The two sulfur stereoisomers share the same connectivity and present different orientations of the oxo and imino groups relative to the core.
Three derivatives retain the same oxoisoindolinyl-substituted tetrahydropyrimidinedione core and terminal phenoxy group. Their linkers contain 12, 16, or 24 oxyethylene repeat units, with the same attachment chemistry at both ends. Each repeat adds two backbone carbons and one ether oxygen, increasing the maximum end-to-end length and the number of rotatable bonds.
A derivative bearing a terminal primary amine couples to activated carboxyl groups on porous agarose beads through an amide bond. The linker projects the oxoisoindolinyl-substituted tetrahydropyrimidinedione core into the aqueous phase inside the packed bed. A buffered sample passes through the bed, and a soluble cereblon-binding ligand competes for the retained protein during elution.
Software attaches candidate linkers at the same core and terminal-group attachment points in molecular graphs. A distance-geometry algorithm generates 100 conformers per candidate, and a molecular mechanics force field minimizes each conformer. The software ranks candidates by the fraction of minimized conformers whose attachment-point separations fall within a specified distance interval.
The substitution count m is 2. Fluorine and methyl occupy neighboring aromatic carbons of the isoindoline ring, with each substituent attached directly to its ring carbon.
Ra6 is ethyl, so R is –N(CH2CH3)–. The nitrogen joins an aromatic carbon of the isoindoline ring to a terminal methylene of L and forms a tertiary amine.
A1 is benzene-1,4-diyl, a1 is 1, and Ry1 is fluorine at carbon 2. The flanking groups attach at carbons 1 and 4.
A2 is trans-cyclobutane-1,3-diyl, y2 is 1, and a2 is 0. The two attachment bonds lie on opposite faces of the four-membered ring at carbons 1 and 3.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A mixture of 5-aminomethyl-2-[(3S)-3-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.85 g, 2.5 mmol), 2-thiophenecarbonyl chloride (0.37 g, 2.5 mmol) and triethylamine (0.51 g, 5.0 mmol) in anhydrous acetonitrile (20 mL) was stirred at room temperature for 1 hour.B · US 2015/0005303 A1 · ¶ 286
A composition comprising a compound selected from compounds of Formula Ia and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof: wherein: R1, R2, R3, R4, R5, and R6 are each independently selected from: H and C1-C6 alkyl;A · US 2014/0206649 A1 · claim 1
In some embodiments, R14 is selected from: methylene, ethylene, cyclopropylene, cyclobutylene, piperidinylene, pyridinylene, tetrahydropyranylene, thiazolylene, cyclohexylene, cyclopentylene, cyclopentenylene, dioxohexahydrothiopyranylene, pyrrolidinylene, tetrahydrothiophenylene, propylene, 3,3-oxetanylene, and —SO2—; wherein said ethylene, methylene, piperidinylene, propylene, and pyrrolidinylene are each optionally substituted with one or more substituents selected from: mA · US 2014/0206649 A1 · ¶ 326
(C0-C10)alkyl-(5 to 10 membered heteroaryl or heterocycle), said heteroaryl or heterocycle optionally substituted with one or more of (C1-C6)alkyl, halogen, oxo, (C1-C6)alkoxy, or —Z—(C1-C6)alkyl, wherein Z is S or SO2, and wherein said (C1-C6)alkyl may be optionally substituted with one or more halogen;B · US 2015/0005303 A1 · ¶
R8 is —R14—R15—R16—R17; wherein: R14 is selected from: C1-C6 alkylene, C3-C7 cycloalkenylene, C3-C7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said C1-C6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: C1-C6 alkoxycarbonyl, C1-C6 alkyl, C3-C7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said C1-C6 alkyl and aryl are optionally substituted with one substituent selected from:A · US 2014/0206649 A1 · ¶ 8
R15 is selected from: —C(O)NH—, —C(O)—, —C(O)O—, C1-C6 alkylene, C3-C7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with C1-C6 alkyl; or R15 is absent;A · US 2014/0206649 A1 · ¶ 8
An empty cell means only that no passage was reproduced there.
Also provided is a composition comprising a compound of Formula Ia or a pharmaceutically acceptable salt, solvate, hydrate, and/or N-oxide thereof, one or more known pharmaceutical agents selected from analgesic agents and antidiabetic agents, and a pharmaceutically acceptable carrier.A · US 2014/0206649 A1 · ¶ 21
A tremendous demand therefore exists for new methods and compositions that can be used to treat patients with cancer.B · US 2015/0005303 A1 · ¶ 4
Accordingly, compounds that can control angiogenesis or inhibit the production of certain cytokines, including TNFα, may be useful in the treatment and prevention of various diseases and conditions.B · US 2015/0005303 A1 · ¶ 7
patent.fyi, US 2026/0356819 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356819/, SHA-256 fe6564173e64747333e9f6e0a3788255fec0ace1357ab54f54c0c2b48d7c9c48